Challenges encountered during the systematic review of newer and enhanced influenza vaccines and recommendations for the future.
influenza vaccines
systematic review
Journal
Reviews in medical virology
ISSN: 1099-1654
Titre abrégé: Rev Med Virol
Pays: England
ID NLM: 9112448
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
31
01
2022
received:
18
11
2021
accepted:
02
02
2022
pubmed:
23
2
2022
medline:
14
9
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
There are a variety of challenges in the conduct of systematic reviews of influenza vaccines. We describe our experience of completing four systematic reviews of newer and enhanced inactivated seasonal influenza vaccines. The reporting of the included studies created significant challenges for study identification, data extraction and analysis. Those challenges have implications for the resources required to conduct reviews and, more significantly, for the accuracy of the estimated treatment effect. There is a substantial burden of morbidity and mortality associated with seasonal influenza, and the evidence used to support vaccination strategies requires regular review. An improved review process will facilitate robust decision-making both nationally and internationally. We recommend the development of reporting guidelines, increased engagement between researchers and decision makers, a database of identified trials, and research into search optimisation.
Substances chimiques
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2335Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project. Journal of Global Health. 2019;9(2):020421.
Comber L, O Murchu E, Jordan K, et al. Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Rev Med Virology. 2021. https://doi.org/10.1002/rmv.2330
Jordan K, O Murchu E, Comber L, et al. Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Rev Med Virology. 2021. https://doi.org/10.1002/rmv.2332
O Murchu E, Comber L, Jordan K, et al. Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Rev Med Virology. 2021. https://doi.org/10.1002/rmv.2329
O Murchu E, Comber L, Jordan K, et al. Systematic review of the efficacy, effectiveness and safety of recombinant HA seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Rev Med Virology. 2021. https://doi.org/10.1002/rmv.2331
Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018;2(CD001269).
World Health Organization. Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations. WHO; 2016.
Moher D. Reporting guidelines: doing better for readers. BMC Med. 2018;16(1):233.